SYS-CON MEDIA Authors: Michael Bushong, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

Investigation Report on China Insulin Glargine Market, 2009-2018

DUBLIN, March 25, 2014 /PRNewswire/ --

Research  and  Markets (http://www.researchandmarkets.com/research/kz2b9w/investigation) has announced the addition of the "Investigation Report on China Insulin Glargine Market, 2009-2018" report to their offering.
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has become a heavy burden on individuals, families, society and governments.

According to statistics from IDF (International Diabetes Federation), the global prevalence rate of diabetes among adults aged 20 to 79 was 8.3% in 2013. The number of diabetes patients has reached 382 million, of which 80% are from medium- and low-income countries where it is still rising rapidly.

It is estimated that by 2035 there will be nearly 592 million people worldwide suffering from diabetes. In the evaluation of diabetes incidence and its trend among various countries and regions, China ranked the first with 98.4 million diabetes patients in 2013, followed by India (65.1 million), the U.S.A. (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that the number of diabetes patients in China will reach 143 million by 2035, which will still be the highest worldwide while that in the U.S.A. will merely reach 29.7 million. Rapid growth of diabetes in China and other developing countries has become an extraordinarily serious burden for these countries' social and economic development.

Insulin glargine is the first long-acting insulin analogue produced through recombinant DNA technology. It was approved for use by FDA (Food and Drug Administration) in April 2000 and EMEA (European Medicines Evaluation Agency) in June 2000. As there is no apparent peak in long-term use of insulin glargine, it has become the most widely used insulin in the United States.

In China, the third-generation insulin is under promotion. Because of the relatively high price, it is mainly used in first-tier cities at present. The second and third generation insulin will be faced with a market pattern of dislocation competition.

Based on CRI's research about certain sample hospitals in China, the CAGR (compound annual growth rate) of sales value of insulin glargine in Chinese sample hospital market exceeded 70% from 2005 to 2013. Human insulin is produced through genetic engineering methods, so a relatively high threshold of production technology is formed. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap, so manufacturers have to attain an industrial production of large scale, low cost and mature technology before gaining profit.


Key  Topics  Covered:

1 Relevant Concepts of Insulin Glargine

2 Market Overview of Insulin Glargine in China

3 Investigation on Sales Value of Insulin Glargine in China, 2009-2013

4 Investigation on Market Share of Major Insulin Glargine Manufacturers in China, 2009-2013

5 Investigation on Market Size of Insulin Glargine by Dosage Form in China, 2009-2013

6 Reference Price of Insulin Glargine in Hospital Market in China, 2013

7 Major Manufacturing Enterprises in China Insulin Glargine Market, 2009-2013

8 Prospect of China Insulin Glargine Market, 2014-2018


Companies  Mentioned:

  • Aventis Behring GmbH
  • Gan & Lee Pharmaceuticals


For more information visit http://www.researchandmarkets.com/research/kz2b9w/investigation


Media  Contact: Laura Wood , +353-1-481-1716, [email protected]


SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.